US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MBX Biosciences

61.60

-1.4000-2.22%

Post-market: 61.600.00000.00%19:30 EDT

Volume:518.30K

Turnover:31.60M

Market Cap:2.97B

PE:-25.61

High:63.04

Open:62.25

Low:59.47

Close:63.00

52wk High:72.64

52wk Low:9.63

Shares:48.16M

Float Shares:27.63M

Volume Ratio:1.63

T/O Rate:1.88%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.4052

EPS(LYR):-2.3824

ROE:-33.17%

ROA:-22.08%

PB:7.24

PE(LYR):-25.86

Loading ...

Overview Company News Filings

MBX Biosciences Inc expected to post a loss of 65 cents a share - Earnings Preview

Mizuho Securities Reaffirms Their Buy Rating on MBX Biosciences, Inc. (MBX)

MBX Biosciences reports Q1 EPS (51c), consensus (58c)

MBX Biosciences appoints Mark Soued as chief commercial officer.

MBX Biosciences posts corporate presentation on endocrine, metabolic disease peptide pipeline

MBX Biosciences Q1 EPS $(0.51) Beats $(0.61) Estimate

Benzinga Earnings

Press Release: MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights

MBX Biosciences grants CCO Mark Soued 160,000 stock options at $29.78 each

MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award

Guggenheim Keeps Their Buy Rating on MBX Biosciences, Inc. (MBX)

Analysts Offer Insights on Healthcare Companies: Teleflex (TFX) and MBX Biosciences, Inc. (MBX)

MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio

MBX Biosciences announces annual shareholder meeting webcast

Microbix Showcases Novel RNA Assay Controls at ESCMID Global 2026

MBX Biosciences grants new chief business officer 130,000 stock options under inducement plan

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MBX Biosciences Advances Avail Phase 2 Trial in Hypoparathyroidism: What Investors Should Watch

MBX Biosciences CFO John W. Smither files initial beneficial ownership statement

MBX Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

MBX Biosciences Chief Makes Bold Insider Move With Major Stock Buy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/MBX/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":61.6,"timestamp":1788206400000,"preClose":63,"halted":0,"volume":518300,"hourTrading":{"tag":"盘后","latestPrice":61.6,"preClose":61.6,"latestTime":"19:30 EDT","volume":36309,"amount":2236605.446662,"timestamp":1788219003434,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0222222222222222,"floatShares":27629899,"shares":48160096,"eps":-2.4052,"marketStatus":"Closed","change":-1.4,"latestTime":"08-31 16:00:00 EDT","open":62.25,"high":63.04,"low":59.47,"amount":31597311.5612,"amplitude":0.056667,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.4052,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":5,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":63,"preHourTrading":{"tag":"盘前","latestPrice":62.91,"preClose":63,"latestTime":"09:27 EDT","volume":3253,"amount":204235.34357,"timestamp":1788182834401,"change":-0.09,"changeRate":-0.001429,"amplitude":0.01291},"postHourTrading":{"tag":"盘后","latestPrice":61.6,"preClose":61.6,"latestTime":"19:30 EDT","volume":36309,"amount":2236605.446662,"timestamp":1788219003434,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.628772,"impliedVol":0.946,"impliedVolPercentile":0.5578},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","floatShares":27629899,"roa":"-22.08%","roe":"-33.17%","lyrEps":-2.382369,"volumeRatio":1.628772,"shares":48160096,"dividePrice":0,"high":63.04,"amplitude":0.056667,"preClose":63,"low":59.47,"week52Low":9.63,"pbRate":"7.24","week52High":72.64,"institutionHeld":0,"latestPrice":61.6,"eps":-2.4052,"divideRate":0,"volume":518300,"delay":0,"ttmEps":-2.4052,"open":62.25,"prevYearClose":31.54,"prevWeekClose":63,"prevMonthClose":65.93,"prevQuarterClose":55.2,"fiveDayClose":66.39,"twentyDayClose":64.41,"sixtyDayClose":30.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"MBX","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.78},{"market":"US","date":"2026-05-07","symbol":"MBX","fiscalQuarterEnding":"2026/03","expectedEps":-0.62,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2026-03-12","symbol":"MBX","fiscalQuarterEnding":"2025/12","expectedEps":-0.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"pre","actualEps":-0.49},{"market":"US","date":"2025-11-06","symbol":"MBX","fiscalQuarterEnding":"2025/09","expectedEps":-0.73,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.63},{"market":"US","date":"2025-08-07","symbol":"MBX","fiscalQuarterEnding":"2025/06","expectedEps":-0.77,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.58}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MBX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":12,"updateTime":1787544000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MBX","date":"2026-08-28","current":-25.611176,"percent":0.06721,"low":-38.854907,"twenty":-18.452139,"median":-13.429759,"eighty":-5.738476,"high":-3.125337,"avg":-13.689012,"sd":8.199835,"marketCap":3197348773},"quantilePoints":[{"date":"2024-09-13","current":-15.960592,"twenty":-13.895501,"median":-10.797864,"eighty":-10.797864,"marketCap":753339957},{"date":"2024-09-20","current":-15.949203,"twenty":-15.694582,"median":-15.111074,"eighty":-12.419885,"marketCap":752802389},{"date":"2024-09-27","current":-16.939398,"twenty":-16.33255,"median":-15.751164,"eighty":-14.917986,"marketCap":799539567},{"date":"2024-10-04","current":-16.797941,"twenty":-16.986079,"median":-16.110499,"eighty":-15.091977,"marketCap":792862827},{"date":"2024-10-11","current":-16.932325,"twenty":-16.986079,"median":-16.31699,"eighty":-15.248994,"marketCap":799205730},{"date":"2024-10-18","current":-17.024271,"twenty":-17.032759,"median":-16.518565,"eighty":-15.369232,"marketCap":803545610},{"date":"2024-10-25","current":-15.022664,"twenty":-17.021442,"median":-16.380645,"eighty":-15.369232,"marketCap":709069745},{"date":"2024-11-01","current":-15.885548,"twenty":-16.991737,"median":-16.362963,"eighty":-15.369232,"marketCap":749797857},{"date":"2024-11-08","current":-13.874718,"twenty":-16.947885,"median":-16.309917,"eighty":-15.248994,"marketCap":765593046},{"date":"2024-11-15","current":-10.66494,"twenty":-16.936569,"median":-16.143706,"eighty":-14.480386,"marketCap":588480730},{"date":"2024-11-22","current":-11.203941,"twenty":-16.918179,"median":-15.949203,"eighty":-13.805677,"marketCap":618222233},{"date":"2024-11-29","current":-12.318278,"twenty":-16.877157,"median":-15.751164,"eighty":-12.380051,"marketCap":679710282},{"date":"2024-12-06","current":-13.432616,"twenty":-16.771064,"median":-15.461179,"eighty":-11.837418,"marketCap":741198331},{"date":"2024-12-13","current":-11.470413,"twenty":-16.663558,"median":-15.31265,"eighty":-11.837418,"marketCap":632925896},{"date":"2024-12-20","current":-12.330391,"twenty":-16.662143,"median":-15.019127,"eighty":-11.803503,"marketCap":680378630},{"date":"2024-12-27","current":-12.154761,"twenty":-16.656485,"median":-14.542475,"eighty":-11.803503,"marketCap":670687579},{"date":"2025-01-03","current":-11.258446,"twenty":-16.435813,"median":-14.054537,"eighty":-11.676323,"marketCap":621229800},{"date":"2025-01-10","current":-8.290916,"twenty":-16.380645,"median":-13.850493,"eighty":-11.492215,"marketCap":457484452},{"date":"2025-01-17","current":-5.989566,"twenty":-16.372157,"median":-13.75965,"eighty":-11.117943,"marketCap":330498264},{"date":"2025-01-24","current":-6.510398,"twenty":-16.36367,"median":-13.256987,"eighty":-10.797864,"marketCap":359237243},{"date":"2025-01-31","current":-6.06224,"twenty":-16.342452,"median":-12.878476,"eighty":-9.893382,"marketCap":334508354},{"date":"2025-02-07","current":-7.473331,"twenty":-16.314161,"median":-12.457571,"eighty":-8.809325,"marketCap":412370938},{"date":"2025-02-14","current":-6.304488,"twenty":-16.290113,"median":-12.324334,"eighty":-7.444262,"marketCap":347875321},{"date":"2025-02-21","current":-6.589128,"twenty":-16.247676,"median":-12.215323,"eighty":-7.171733,"marketCap":363581507},{"date":"2025-02-28","current":-5.813937,"twenty":-16.175534,"median":-12.009413,"eighty":-6.798672,"marketCap":320807212},{"date":"2025-03-07","current":-5.989566,"twenty":-16.064646,"median":-11.803503,"eighty":-6.591551,"marketCap":330498264},{"date":"2025-03-14","current":-5.26888,"twenty":-15.958314,"median":-11.682379,"eighty":-6.514032,"marketCap":290731536},{"date":"2025-03-21","current":-4.258879,"twenty":-15.936472,"median":-11.549143,"eighty":-6.294798,"marketCap":263718287},{"date":"2025-03-28","current":-4.188707,"twenty":-15.858671,"median":-11.258446,"eighty":-6.213645,"marketCap":259373118},{"date":"2025-04-04","current":-3.260282,"twenty":-15.749749,"median":-11.107042,"eighty":-6.057395,"marketCap":201883200},{"date":"2025-04-11","current":-3.999783,"twenty":-15.687509,"median":-10.797864,"eighty":-5.922948,"marketCap":247674589},{"date":"2025-04-17","current":-4.113138,"twenty":-15.461179,"median":-10.66494,"eighty":-5.686757,"marketCap":254693707},{"date":"2025-04-25","current":-4.949799,"twenty":-15.461179,"median":-9.901861,"eighty":-5.438453,"marketCap":306501482},{"date":"2025-05-02","current":-6.477382,"twenty":-15.454106,"median":-9.653557,"eighty":-5.327647,"marketCap":401092452},{"date":"2025-05-09","current":-5.996976,"twenty":-15.31265,"median":-8.539219,"eighty":-5.438453,"marketCap":371344761},{"date":"2025-05-16","current":-5.077465,"twenty":-15.206557,"median":-7.473331,"eighty":-5.077465,"marketCap":373015980},{"date":"2025-05-23","current":-5.691675,"twenty":-15.022664,"median":-7.246225,"eighty":-5.226487,"marketCap":418138881},{"date":"2025-05-30","current":-5.787218,"twenty":-15.017006,"median":-7.134185,"eighty":-5.260401,"marketCap":425157999},{"date":"2025-06-06","current":-5.395944,"twenty":-14.885451,"median":-6.813207,"eighty":-5.315894,"marketCap":396413040},{"date":"2025-06-13","current":-4.877278,"twenty":-14.35621,"median":-6.707223,"eighty":-5.172099,"marketCap":358309257},{"date":"2025-06-20","current":-4.677092,"twenty":-14.130289,"median":-6.595185,"eighty":-5.059804,"marketCap":343602533},{"date":"2025-06-27","current":-5.136611,"twenty":-14.052953,"median":-6.564904,"eighty":-5.017962,"marketCap":377361148},{"date":"2025-07-03","current":-5.673476,"twenty":-13.977856,"median":-6.515167,"eighty":-5.013234,"marketCap":416801906},{"date":"2025-07-11","current":-5.641628,"twenty":-13.855338,"median":-6.4303,"eighty":-5.035235,"marketCap":414462200},{"date":"2025-07-18","current":-5.548359,"twenty":-13.804466,"median":-6.320845,"eighty":-5.055522,"marketCap":407610204},{"date":"2025-07-25","current":-5.928259,"twenty":-13.766918,"median":-6.298431,"eighty":-5.072006,"marketCap":435519554},{"date":"2025-08-01","current":-6.028352,"twenty":-13.628836,"median":-6.310434,"eighty":-5.101123,"marketCap":442872915},{"date":"2025-08-08","current":-4.830149,"twenty":-13.362364,"median":-6.283291,"eighty":-5.101123,"marketCap":372013249},{"date":"2025-08-15","current":-5.76189,"twenty":-13.198847,"median":-6.22399,"eighty":-5.101123,"marketCap":443774969},{"date":"2025-08-22","current":-6.171895,"twenty":-13.089836,"median":-6.221845,"eighty":-5.14935,"marketCap":475353203},{"date":"2025-08-29","current":-6.224236,"twenty":-12.914207,"median":-6.224236,"eighty":-5.170279,"marketCap":479384467},{"date":"2025-09-05","current":-5.635398,"twenty":-12.685283,"median":-6.241684,"eighty":-5.176649,"marketCap":434032748},{"date":"2025-09-12","current":-4.331231,"twenty":-12.593229,"median":-6.221845,"eighty":-5.070186,"marketCap":333587089},{"date":"2025-09-19","current":-4.392296,"twenty":-12.449092,"median":-6.213645,"eighty":-5.008506,"marketCap":338290230},{"date":"2025-09-26","current":-10.057984,"twenty":-12.39822,"median":-6.217295,"eighty":-5.008506,"marketCap":774655869},{"date":"2025-10-03","current":-9.721364,"twenty":-12.327968,"median":-6.224236,"eighty":-5.029502,"marketCap":748729706},{"date":"2025-10-10","current":-9.207959,"twenty":-12.309799,"median":-6.253122,"eighty":-5.039662,"marketCap":709187798},{"date":"2025-10-17","current":-7.994552,"twenty":-12.25166,"median":-6.280939,"eighty":-5.051241,"marketCap":615732407},{"date":"2025-10-24","current":-9.364715,"twenty":-12.13417,"median":-6.307461,"eighty":-5.070186,"marketCap":721260982},{"date":"2025-10-31","current":-12.650784,"twenty":-12.13417,"median":-6.352937,"eighty":-5.089294,"marketCap":974350701},{"date":"2025-11-07","current":-13.743232,"twenty":-12.309799,"median":-6.369154,"eighty":-5.142981,"marketCap":1106261420},{"date":"2025-11-14","current":-13.426901,"twenty":-12.512852,"median":-6.477382,"eighty":-5.169369,"marketCap":1080798409},{"date":"2025-11-21","current":-15.07807,"twenty":-12.739549,"median":-6.521866,"eighty":-5.176649,"marketCap":1213709223},{"date":"2025-11-28","current":-19.239461,"twenty":-13.256987,"median":-6.567932,"eighty":-5.191208,"marketCap":1548680395},{"date":"2025-12-05","current":-17.036043,"twenty":-13.72255,"median":-6.589128,"eighty":-5.211681,"marketCap":1371316303},{"date":"2025-12-12","current":-15.859028,"twenty":-13.826268,"median":-6.619611,"eighty":-5.226487,"marketCap":1276572445},{"date":"2025-12-19","current":-15.992906,"twenty":-14.046615,"median":-6.70403,"eighty":-5.26888,"marketCap":1287348998},{"date":"2025-12-26","current":-17.911832,"twenty":-14.268105,"median":-6.806351,"eighty":-5.279538,"marketCap":1441812917},{"date":"2026-01-02","current":-17.59387,"twenty":-14.917986,"median":-6.813207,"eighty":-5.295223,"marketCap":1416218605},{"date":"2026-01-09","current":-17.136452,"twenty":-15.146199,"median":-7.076651,"eighty":-5.307262,"marketCap":1379398717},{"date":"2026-01-16","current":-22.820712,"twenty":-15.452731,"median":-7.200803,"eighty":-5.317689,"marketCap":1836953174},{"date":"2026-01-23","current":-23.646296,"twenty":-15.472295,"median":-7.424882,"eighty":-5.324948,"marketCap":1903408581},{"date":"2026-01-30","current":-20.550355,"twenty":-15.847871,"median":-7.61062,"eighty":-5.334947,"marketCap":1654200805},{"date":"2026-02-06","current":-20.109671,"twenty":-15.97998,"median":-7.994552,"eighty":-5.365916,"marketCap":1618727987},{"date":"2026-02-13","current":-22.260078,"twenty":-16.085028,"median":-8.265761,"eighty":-5.405044,"marketCap":1791824944},{"date":"2026-02-20","current":-21.826592,"twenty":-16.300015,"median":-8.354645,"eighty":-5.422333,"marketCap":1756931510},{"date":"2026-02-27","current":-20.526135,"twenty":-16.365085,"median":-8.65641,"eighty":-5.437203,"marketCap":1652251211},{"date":"2026-03-06","current":-18.414356,"twenty":-16.656674,"median":-8.777334,"eighty":-5.439664,"marketCap":1482263608},{"date":"2026-03-13","current":-15.268438,"twenty":-16.663558,"median":-8.888641,"eighty":-5.448143,"marketCap":1327911291},{"date":"2026-03-20","current":-15.530651,"twenty":-16.662191,"median":-9.207959,"eighty":-5.4632,"marketCap":1350716208},{"date":"2026-03-27","current":-15.454172,"twenty":-16.656674,"median":-9.44019,"eighty":-5.477809,"marketCap":1344064774},{"date":"2026-04-02","current":-17.639279,"twenty":-16.656721,"median":-9.686541,"eighty":-5.527885,"marketCap":1534105746},{"date":"2026-04-10","current":-17.950657,"twenty":-16.797941,"median":-9.847355,"eighty":-5.527885,"marketCap":1561186584},{"date":"2026-04-17","current":-18.147317,"twenty":-16.939398,"median":-9.944254,"eighty":-5.546084,"marketCap":1578290272},{"date":"2026-04-24","current":-18.240184,"twenty":-16.993812,"median":-10.091627,"eighty":-5.548359,"marketCap":1586367013},{"date":"2026-05-01","current":-16.529418,"twenty":-17.017199,"median":-10.162452,"eighty":-5.565633,"marketCap":1437580056},{"date":"2026-05-08","current":-19.051466,"twenty":-17.024271,"median":-10.419594,"eighty":-5.573382,"marketCap":1651171534},{"date":"2026-05-15","current":-19.432949,"twenty":-17.098465,"median":-10.797864,"eighty":-5.623429,"marketCap":1683048872},{"date":"2026-05-22","current":-17.470969,"twenty":-17.116218,"median":-10.949581,"eighty":-5.635398,"marketCap":1513125669},{"date":"2026-05-29","current":-17.531422,"twenty":-17.244113,"median":-11.182744,"eighty":-5.640382,"marketCap":1518361398},{"date":"2026-06-05","current":-16.987343,"twenty":-17.244113,"median":-11.332873,"eighty":-5.647113,"marketCap":1471239837},{"date":"2026-06-12","current":-20.471645,"twenty":-17.244113,"median":-11.549143,"eighty":-5.650278,"marketCap":1773008216},{"date":"2026-06-18","current":-22.856798,"twenty":-17.305607,"median":-11.667238,"eighty":-5.653457,"marketCap":1979581522},{"date":"2026-06-26","current":-27.68206,"twenty":-17.435508,"median":-11.803503,"eighty":-5.659497,"marketCap":2397487888},{"date":"2026-07-02","current":-30.732198,"twenty":-17.480357,"median":-11.965702,"eighty":-5.666777,"marketCap":2661654213},{"date":"2026-07-10","current":-36.112531,"twenty":-17.527026,"median":-11.991245,"eighty":-5.673476,"marketCap":3127634090},{"date":"2026-07-17","current":-32.051177,"twenty":-17.634503,"median":-12.154761,"eighty":-5.678788,"marketCap":2775888299},{"date":"2026-07-24","current":-34.936442,"twenty":-17.867538,"median":-12.324334,"eighty":-5.688724,"marketCap":3025775363},{"date":"2026-07-31","current":-36.524712,"twenty":-17.911832,"median":-12.436374,"eighty":-5.691675,"marketCap":3163332242},{"date":"2026-08-07","current":-30.628146,"twenty":-17.994359,"median":-12.627144,"eighty":-5.692585,"marketCap":3194270640},{"date":"2026-08-14","current":-30.97629,"twenty":-18.158049,"median":-12.72465,"eighty":-5.698044,"marketCap":3230579239},{"date":"2026-08-21","current":-30.63919,"twenty":-18.368939,"median":-13.111638,"eighty":-5.710784,"marketCap":3195422369},{"date":"2026-08-28","current":-30.657661,"twenty":-18.452139,"median":-13.429759,"eighty":-5.738476,"marketCap":3197348773}],"updateTime":1788222752772},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MBX\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633446829","title":"MBX Biosciences Inc  expected to post a loss of 65 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633446829","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633446829?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:55","pubTimestamp":1778255708,"startTime":"0","endTime":"0","summary":"MBX Biosciences Inc  expected to post a loss of65cents a share - Earnings Preview MBX Biosciences Inc MBX.OQ MBX.O is expected to  show no change in quarterly revenue when it reports  results on Augus","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1YS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633051471","title":"Mizuho Securities Reaffirms Their Buy Rating on MBX Biosciences, Inc. (MBX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633051471","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633051471?lang=en_us&edition=fundamental","pubTime":"2026-05-08 06:55","pubTimestamp":1778194545,"startTime":"0","endTime":"0","summary":"In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on MBX Biosciences, Inc., with a price target of $57.00. Ear cove...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-reaffirms-their-buy-rating-on-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-reaffirms-their-buy-rating-on-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","MFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633176351","title":"MBX Biosciences reports Q1 EPS (51c), consensus (58c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633176351","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633176351?lang=en_us&edition=fundamental","pubTime":"2026-05-08 03:50","pubTimestamp":1778183445,"startTime":"0","endTime":"0","summary":"“We continue to make excellent progress across our pipeline in 2026, including advancement toward initiation of our Phase 3 trial of once-weekly ca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-reports-q1-eps-51c-consensus-58c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-reports-q1-eps-51c-consensus-58c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633178095","title":"MBX Biosciences appoints Mark Soued as chief commercial officer.","url":"https://stock-news.laohu8.com/highlight/detail?id=2633178095","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633178095?lang=en_us&edition=fundamental","pubTime":"2026-05-08 02:59","pubTimestamp":1778180372,"startTime":"0","endTime":"0","summary":"MBX Biosciences (MBX) announced the appointment of Mark Soued as chief commercial officer. Most recently, Soued served as senior VP, head of U.S. a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-appoints-mark-soued-as-chief-commercial-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-appoints-mark-soued-as-chief-commercial-officer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633425401","title":"MBX Biosciences posts corporate presentation on endocrine, metabolic disease peptide pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2633425401","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633425401?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:25","pubTimestamp":1778156741,"startTime":"0","endTime":"0","summary":"MBX Biosciences outlined plans to start Phase 3 trial for once-weekly hypoparathyroidism therapy canvuparatide  in Q3 2026.Phase 2 Avail trial showed 63% responder rate at week 12; open-label extension showed 79% responder rate at 6 months; no treatment-related serious adverse events or discontinuations reported in 12-week trial.Program update flagged Avail Phase 2 presentation with one-year open-label extension data at ENDO 2026.Pipeline milestones include Phase 2a results for imapextide  in Q2 2026; Phase 1 12-week multiple-ascending-dose results for obesity candidate MBX 4291  in Q4 2026.Cash and investments of $440 million as of March 31, 2026, cited as funding runway into 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Bi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL6KpxjX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633401144","title":"MBX Biosciences Q1 EPS $(0.51) Beats $(0.61) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633401144","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633401144?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:13","pubTimestamp":1778156004,"startTime":"0","endTime":"0","summary":"MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.61) by 16.39 percent. This is a 28.17 percent increase over losses of $(0.71) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52363358/mbx-biosciences-q1-eps-0-51-beats-0-61-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633338144","title":"Press Release: MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633338144","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633338144?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:01","pubTimestamp":1778155260,"startTime":"0","endTime":"0","summary":"Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in June 2026. Phase 3 trial of once-weekly canvuparatide on track to initiate in Q3 2026. Appointment of Mark Soued as Chief Commercial Officer adds launch and commercialization expertise. Company to host Obesity Day on May 11 featuring initial blinded data from ongoing MBX 4291 Phase 1 trial and update on expanding obesity portfolio. \"We continue to make excellent progress across our pipeline in 2026, including advancement toward initiation of our Phase 3 trial of once-weekly canvuparatide following a successful End-of-Phase 2 meeting with the FDA,\" said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. \"Now we look forward to presenting our full Phase 2 Avail results, including one-year open-label extension data for canvuparatide, while continuing to advance a growing obesity pipeline enabled by our Precision Endocrine Peptide  platform. With a world-class leadership ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4007","MBX","BK4099","BK4585","BK4588","PBH","BK4022","BK4604","03160","BK4232","BK4555","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633145621","title":"MBX Biosciences grants CCO Mark Soued 160,000 stock options at $29.78 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2633145621","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633145621?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:05","pubTimestamp":1778151954,"startTime":"0","endTime":"0","summary":"MBX Biosciences granted new Chief Commercial Officer Mark R. Soued non-qualified stock options for 160,000 shares under its 2026 Inducement Plan, tied to his appointment.Options carry an exercise price of $29.78 per share, matching Nasdaq closing price on May 1, 2026.Award has a 10-year term; 25% vests on one-year anniversary of April 29, 2026; remainder vests in 36 equal monthly installments over next three years, subject to continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL9zX9pV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914580","title":"MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914580","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914580?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"CARMEL, Ind. and BURLINGTON, Mass., May  07, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289809/0/en/MBX-Biosciences-Announces-Appointment-of-Mark-Soued-as-Chief-Commercial-Officer-and-Inducement-Grant-Award.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","HP","LU0823414551.USD","BK4007","BK4009","LU2506951792.HKD","LU2294711713.HKD","BK4092","PBH","LU2357125470.USD","LU2249611893.SGD","CCO","LU0823414478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632930369","title":"Guggenheim Keeps Their Buy Rating on MBX Biosciences, Inc. (MBX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632930369","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632930369?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:17","pubTimestamp":1777893461,"startTime":"0","endTime":"0","summary":"In a report released today, Seamus Fernandez from Guggenheim maintained a Buy rating on MBX Biosciences, Inc., with a price target of $88.00. Ferna...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629646890","title":"Analysts Offer Insights on Healthcare Companies: Teleflex (TFX) and MBX Biosciences, Inc. (MBX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629646890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629646890?lang=en_us&edition=fundamental","pubTime":"2026-04-24 14:40","pubTimestamp":1777012850,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teleflex (TFX) and MBX Biosciences, Inc. (MBX). Teleflex (TFX) In...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-teleflex-tfx-and-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-teleflex-tfx-and-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4585","LU0128526141.USD","LU0029874061.USD","BK4588","TFX","BK4007","LABU","XBI","BK4581","XLV","BK4504","MBX","BK4082","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629839523","title":"MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2629839523","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629839523?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:00","pubTimestamp":1776945600,"startTime":"0","endTime":"0","summary":"CARMEL, Ind. and BURLINGTON, Mass., April  23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commer","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3279842/0/en/MBX-Biosciences-to-Host-In-Person-and-Virtual-Obesity-Day-on-May-11-2026-to-Discuss-Expanding-Obesity-Portfolio.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4585","BK4092","BK4588","PBH","MBX","BK4181","BK4007","HP","HST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629404633","title":"MBX Biosciences announces annual shareholder meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2629404633","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629404633?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:05","pubTimestamp":1776859521,"startTime":"0","endTime":"0","summary":"MBX Biosciences scheduled 2026 annual shareholder meeting to be held online June 4, 2026.Shareholders will vote to elect two Class II directors, with terms running to 2029.Meeting agenda also includes ratification of Ernst & Young as independent registered public accounting firm for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL9P0JDb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627158281","title":"Microbix Showcases Novel RNA Assay Controls at ESCMID Global 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2627158281","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627158281?lang=en_us&edition=fundamental","pubTime":"2026-04-15 19:58","pubTimestamp":1776254304,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Microbix Biosystms ( ($TSE:MBX) ). Microbix Biosystems will exhibit at ESCMID Global 2026 in Munich, where it p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-showcases-novel-rna-assay-controls-at-escmid-global-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-showcases-novel-rna-assay-controls-at-escmid-global-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4588","BK4505","RNA","IE0009354923.USD","BK4139","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624657872","title":"MBX Biosciences grants new chief business officer 130,000 stock options under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2624657872","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624657872?lang=en_us&edition=fundamental","pubTime":"2026-04-03 20:00","pubTimestamp":1775217616,"startTime":"0","endTime":"0","summary":"MBX Biosciences granted non-qualified stock options covering 130,000 shares to new Chief Business Officer Karen Basbaum under its 2026 Inducement Plan.Options carry an exercise price of $32.29 per share.Vesting starts with 25% on March 9, 2027.Remaining options vest in equal monthly installments over the next three years, subject to continued service.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDLby3JrQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BN0W2T93.GBP","BK4585","IE00B3QW5Z07.USD","MBX","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","NDAQ","SG9999014005.SGD","LU0314104364.USD","BK4007","LU2095319765.USD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4112","SG9999014021.USD","LU2210150020.SGD","BK4588","IE00BN0W2W23.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624165799","title":"MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624165799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624165799?lang=en_us&edition=fundamental","pubTime":"2026-04-03 20:00","pubTimestamp":1775217600,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., April  03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/03/3267994/0/en/MBX-Biosciences-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4092","PBH","HP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621709758","title":"MBX Biosciences Advances Avail Phase 2 Trial in Hypoparathyroidism: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2621709758","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621709758?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:30","pubTimestamp":1774024245,"startTime":"0","endTime":"0","summary":"MBX Biosciences, Inc. ($MBX) announced an update on their ongoing clinical study. The Avail Phase 2 trial from MBX Biosciences, Inc. tests a new we...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-advances-avail-phase-2-trial-in-hypoparathyroidism-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-advances-avail-phase-2-trial-in-hypoparathyroidism-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","BK4007","MBX","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620826475","title":"MBX Biosciences CFO John W. Smither files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620826475","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620826475?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:06","pubTimestamp":1773864395,"startTime":"0","endTime":"0","summary":"MBX Biosciences reported an initial statement of beneficial ownership for John Smither, its chief financial officer. The filing listed no securities as beneficially owned by Smither. The date of the event requiring the statement was 03/16/2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL1kXLj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620261420","title":"MBX Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2620261420","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620261420?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:32","pubTimestamp":1773754337,"startTime":"0","endTime":"0","summary":"MBX Biosciences Inc reports results for the quarter ended December 31 - Earnings SummaryMBX Biosciences Inc MBX.OQ reported a quarterly adjusted loss of 49 cents per share for the quarter ended Decemb","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL8N4051DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620929411","title":"MBX Biosciences Chief Makes Bold Insider Move With Major Stock Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2620929411","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620929411?lang=en_us&edition=fundamental","pubTime":"2026-03-17 10:09","pubTimestamp":1773713390,"startTime":"0","endTime":"0","summary":"New insider activity at MBX Biosciences, Inc. ( ($MBX) ) has taken place on March 16, 2026. MBX Biosciences, Inc. has seen a notable insider move a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/mbx-biosciences-chief-makes-bold-insider-move-with-major-stock-buy-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/mbx-biosciences-chief-makes-bold-insider-move-with-major-stock-buy-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":113,"code":"91000000","status":"200"}]}}